INTRODUCTION {#s1}
============

Chronic kidney disease (CKD) is quite a common disease around the world, its etiology from infectious disease to emerging diseases especially hypertension and diabetes \[[@R1]--[@R3]\]. CKD increases a large burden for our society for its highly associated morbidity and mortality, mainly elevated cardiovascular system diseases \[[@R4], [@R5]\]. In clinical therapy, there are different related therapy ways during CKD patients' different period, the most common therapy ways like dialysis and renal transplantation.

Renal transplantation is regarded as the therapeutic option of choice in the end-stage renal failure \[[@R6]\]. Initially, for transplant recipients, the *de novo* malignancy is the only sideline of this population, since tumor-specific mortality is not the main reason of the population \[[@R7]\]. However, with the judicious use of better immunosuppressive agents, it dramatically decreases the incidence of acute graft rejection and long-term outcome can be enhanced \[[@R8], [@R9]\]. At the same time, it increases the risk of variety of new malignancies. The most common of these malignancies are skin cancers and lymphomas, followed by Kaposi, sarcoma, lip, cervical, perineal, renal, hepatocellular carcinomas and other sarcomas \[[@R10], [@R11]\].

Hepatocellular carcinoma (HCC) is also a common tumor worldwide, it's popularity has related geographic differences. Epidemiology revealed that areas with high incidence include Africa, in Asia especially southeastern countries (Korea, Hong Kong, Thailand), however, in majority areas of China and Japan. Its main risk factors are hepatitis virus infection like hepatitis B and hepatitis C, the other susceptible factors are alcohol consumption, aflatoxin B1 intake and other associated congenital diseases \[[@R12]\].

Some studies have showed the increased risk of liver carcinoma after renal transplantation \[[@R13], [@R14]\]. However, not all studies showed similar association around the world, it may relate to the geography and population difference. Because of differences in study design, sample selection, sample size, follow-up period, and population and geographic differences, the connection between renal transplantation and liver carcinoma remains unclear. So this meta-analysis, which included all relevant studies on liver carcinoma and renal transplantation, was performed to clarify whether the total standardized incidence rate (SIR) of liver carcinoma is higher following renal transplantation than in the general population, which might be helpful in determining whether conclusive recommendations for liver cancer screening in renal transplantation recipients are needed.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 9 studies met our inclusion criteria \[[@R13], [@R15]--[@R22]\]. These 9 articles, which included 17,4256 renal transplantation recipients in 25,7206 patients, evaluated whether the total SIR for liver cancer was higher in renal transplant recipients than in the general population. An outline for the selection process of identified studies is presented in Figure [1](#F1){ref-type="fig"}. The main characteristics of the studies and their details are listed in Table [1](#T1){ref-type="table"}. All the studies were retrospective, and the largest study had 12,0654 renal transplant recipients. These related studies were based on patients in several countries, including Italy, China, Sweden, the USA, the UK, Canada and Japan.

![Flow chart of literature search and study selection](oncotarget-08-68928-g001){#F1}

###### Summary of studies included in the analysis

  Study            Year   Type of transplant   Data source                                                 Geographicorigin   Number of patients (n)   Number of kidneytransplant cases
  ---------------- ------ -------------------- ----------------------------------------------------------- ------------------ ------------------------ ----------------------------------
  **Piselli**      2013   Kidney               Italian KT centre                                           Italy              7217                     7299
  **Cheung**       2012   Kidney               Hong Kong Renal Registry                                    China              4674                     4895
  **Krynitz**      2012   multiorgan           Swedish National Patient Register                           Sweden             10476                    7952
  **Li**           2012   Kidney               Taiwan National Health InsuranceResearch Database (NHIRD)   China              4716                     4716
  **Engels**       2011   multiorgan           Scientific Registry of Transplant Recipients                U.S.               175732                   120654
  **Collett**      2010   multiorgan           UK Transplant Registry                                      UK                 37617                    25104
  **Serraino**     2007   multiorgan           No mention                                                  Italy              2875                     1892
  **Villeneuve**   2007   multiorgan           Canadian cancer registry                                    Canada             11155                    11 391
  **Hoshida**      1997   multiorgan           Multicentre Japan                                           Japan              2744                     1744
  **Total**        ---    ---                  ---                                                         ---                **257206**               **174256**

Table [2](#T2){ref-type="table"} shows summary of the included studies in our analysis with details of the studies. As noted, the 257206 renal transplant recipients were included in this analysis were followed up for a total of 256736 person-years, with a mean follow-up duration of 7. 6125 years (range: 4.8 - 16.0 years). The mean age at transplantation were 44.77 (range: 41.5 - 47.3) years old. Of the 9136 cases that developed cancers and hematological malignancies, this meta-analysis identified 185 cases of liver cancer compared to 84.12 expected cases.

###### Demographic details of patients in the included studies

  Study            Year      Length of follow-up time   Number of all cancers (n) in kidney transplant cases   Mean follow-up time(years)   Patient-years (years)   Mean age at transplantation (years)   Number of expected cases of liver cancer   Number of identified cases of liver cancers
  ---------------- --------- -------------------------- ------------------------------------------------------ ---------------------------- ----------------------- ------------------------------------- ------------------------------------------ ---------------------------------------------
  **Piselli**      2013      1997--2009                 395                                                    5.5                          39598.0                 ---                                   9.40                                       4
  **Cheung**       2012      1972--2011                 299                                                    8.2                          40 246                  47.3                                  7.92                                       20
  **Krynitz**      2012      1970-2008                  2774                                                   5.1                          93432                   ---                                   ---                                        20
  **Li**           2012      1997--2008                 320                                                    4.8                          22556                   41.5                                  11.80                                      60
  **Engels**       2011      1987--2008                 ---                                                    ---                          ---                     ---                                   44.50                                      48
  **Collett**      2010      1980-2007                  4420                                                   16.0                         ---                     ---                                   7.80                                       19
  **Serraino**     2007      ---                        104                                                    6.5                          6931                    45.50                                 ---                                        6
  **Villeneuve**   2007      1981--1998                 778                                                    7.4                          81237                   ---                                   2.70                                       5
  **Hoshida**      1997      1970--1995                 46                                                     7.4                          12982                   ---                                   ---                                        3
  **Total**        **---**   **---**                    **9136**                                               **7.6125**                   **256736**              **44.77**                             **84.12**                                  **185**

Evidence analysis {#s2_2}
-----------------

This meta-analysis for the SIR for liver cancer suggested a significantly increased risk compared to the common population (SIR=2.08, 95%CI: 1.24-3.47; P=0.005; Table [3](#T3){ref-type="table"}). Figure [2](#F2){ref-type="fig"} shows forest plots for individual and overall RR measures. There was heterogeneity (*I^2^*=89.2%, P ~heterogeneity~=0.000) in the pooled analysis.

###### Overall SIR and 95% CI in our meta-analysis

  Study            Year      SIR         95% Confidence intervals   
  ---------------- --------- ----------- -------------------------- -----------
  **Piselli**      2013      0.40        0.10                       1.10
  **Cheung**       2012      2.53        1.63                       3.91
  **Krynitz**      2012      2.70        1.60                       4.10
  **Li**           2012      5.07        3.89                       6.42
  **Engels**       2011      1.08        0.80                       1.43
  **Collett**      2010      2.40        1.50                       3.80
  **Serraino**     2007      4.00        1.50                       8.70
  **Villeneuve**   2007      1.80        0.60                       4.30
  **Hoshida**      1997      1.36        0.24                       3.36
  **Combined**     **---**   **2.178**   **1.360**                  **3.488**

![Forest plots of the relative ratios (RRs) and 95% confidence intervals (CIs) for overall risk of liver cancer\
The squares and horizontal lines correspond to the study-specific RR and 95% CI. The area of the squares reflects the study specific weight.](oncotarget-08-68928-g002){#F2}

Sensitivity analysis assessed the influence of an individual study on the pooled RR by omitting one study and re-analyzing the results. Our sensitivity analysis indicates the omission of any of the studies led to changes in estimates between 1.844(95%CI=1.209 - 2.814) and 2.428(95%CI=1.579 - 3.733; Table [4](#T4){ref-type="table"}). In assessing the association of renal transplantation with the risk of liver cancer risk, we found that no individual altered the significance of the RRs, suggesting the stability and reliability of the overall results (Figure [3](#F3){ref-type="fig"}). With limited information available, we could not detect any sources contributing to the substantial heterogeneity. Potential publication bias of the studies was assessed using Funnel plots and Begg's and Egger's tests. Funnel plot asymmetry was not observed. Publication bias was not evident (t= −0.79, p=0.457) (Figure [4](#F4){ref-type="fig"}).

###### Sensitivity analysis

  Study            Year      SIR         95% Confidence intervals   
  ---------------- --------- ----------- -------------------------- -----------
  **Piselli**      2013      2.400       1.439                      4.003
  **Cheung**       2012      1.997       1.101                      3.623
  **Krynitz**      2012      1.982       1.101                      3.571
  **Li**           2012      1.844       1.209                      2.814
  **Engels**       2011      2.428       1.579                      3.733
  **Collett**      2010      2.015       1.117                      3.635
  **Serraino**     2007      1.926       1.111                      3.341
  **Villeneuve**   2007      2.103       1.215                      3.642
  **Hoshida**      1997      2.146       1.253                      3.675
  **Combined**     **---**   **2.077**   **1.244**                  **3.471**

![Results of sensitivity analysis liver cancer risk in renal transplant recipients](oncotarget-08-68928-g003){#F3}

![Begg's funnel plots of liver cancer risk across all related populations](oncotarget-08-68928-g004){#F4}

DISCUSSION {#s3}
==========

Our collected data suggests that the increased risk of developing liver cancer in renal transplantation compared with general population (SIR=2.077, 95% CI= 1.244 - 3.471, P=0.005). Tumors such as NHL and Kaposi's carcinoma, which are rare in the general population, however, are encountered more frequently in solid organ transplantation recipients \[[@R23]\]. Liver carcinoma prevails around the world, the difference of the prevalence and mortality exists due to the genetic background and regional environmental difference. Among the solid organ transplant recipients (e g: kidney transplantation recipients), its incidence rate also enhanced with the organ transplantation \[[@R13], [@R17], [@R22]\]. In this meta-analysis, our collected data provide further evidence that renal transplantation recipients are at more risk of liver carcinoma than the general population.

The exact mechanisms of the oncogenesis in renal transplantation recipients are still unknown. Several possible related factors had been proposed. One hypothesis is that cancers result from related viral infection(hepatitis B virus or hepatitis C virus related) and another is reduced immune surveillance against a variety of non-viral tumor antigens \[[@R24]\]. For a part of renal transplant recipients, they were also chronic B virus carrier at the same time and this figure were similar to the local general population \[[@R13]\]. Organ transplant recipients are vulnerable to viral infection or reactivation of latent infection because the initiation of immunosuppressive agents may promote the unchecked viral replication. In this situation that hepatitis virus infected patients with renal transplant, physicians should check virus quantitative at regular intervals, then take corresponding efforts of anti-virus therapy. At the same time, clinical doctors should attach great importance on immunosuppressive agents treatment period and dosage, in order to prevent hepatitis virus reactivation among patients with viral hepatitis. For the end-stage kidney disease (ESKD) patients, dialysis is one important therapy and it can prolong patients' media kidney transplant age. A great proportion of patients are usually infected before renal transplantation while using hemodialysis facilities. Previous studies demonstrated that hepatitis C has a wide range of prevalence among renal transplant recipients living in different countries \[[@R25], [@R26]\]. Some important factors that have an impact on HCV infection in subjects receiving hemodialysis facilities are as follows: race, geographic origin of the recipients \[[@R27]\], type of dialysis \[[@R28]--[@R30]\], number of blood transfusion \[[@R27], [@R31]\], history of organ transplantation \[[@R32]\] and hepatitis B virus co-infection. In Italy, among dialysis patients, the prevalence with HBV and or with HCV is high \[[@R33]\]. Because of renal failure, some dialysis patients need some blood transfusion, the potential reason for this situation is due to the lack of erythropoietin which is mainly produced by the kidney \[[@R34]\], then entire body manifest a series of symptoms of anemia like breathlessness, dizziness, poor appetite and decreased exercise tolerance. Some essays reported that hepatitis C is a major cause of transfusion associated hepatitis and also a leading cause of chronic liver disease in transplant recipients \[[@R35], [@R36]\]. It is also a cause of chronic hepatitis in approximately 10% of all renal transplant recipients \[[@R35]\]. In order to prevent the occurrence of this phenomenon, regarding to the patients of non-infected hepatitis virus recipients, medical organization should pay much attention to the medical facilities. In addition to hepatitis C virus, hepatitis B virus (HBV) is a well-known oncogenic virus and the main risk for hepatocellular carcinoma development. For hepatitis B virus (HBV) infected patients, occult HBV infection is special infected situation in the human body \[[@R37], [@R38]\]. Occult hepatitis B infection(OBI) is the presence of hepatitis B virus (HBV) DNA in serum or hepatic tissue without detectable hepatitis B virus surface antigen (HBsAg) in serum \[[@R39]\]. Occult hepatitis B infection may be reactivated, then resulting in acute and severe patterns of hepatitis B virus, which may also occur after transmission of OBI by transfusion or organ transplant. Immunosuppressed and cirrhotic individuals with OBI prone to viral reactivation and hepatocellular transformation \[[@R37]\], so it requires the usage of highly sensitive and specific molecular biology techniques. In the human body, some patients are involved in the immunosuppression situation with acquired immune deficiency such as those with HIV and AIDS (especially HIV popular region). Although the majority of the elevated site-specific cancer risks appear to be driven mostly by immune suppression, linked with oncogenic viral or bacterial infections \[[@R40]\], tumor-promoting effects of the immunosuppressive drugs themselves may also contribute \[[@R41]\]. The long term use of immunosuppressive therapy for the graft is another possible factor promoting liver cancer, as reported for other malignancies \[[@R17], [@R22], [@R42]\]. Indeed, immunosuppression resulting from inherited deficiency, AIDS or drugs, has been associated with a higher risk of malignancy than in a immunocompetent population \[[@R43]\]. Immunosuprssive regiments such as azathioprine, prednisolone and cyclosporine have been used commonly in recent decades and carry similar risks for carcinogenicity after kidney transplantation \[[@R44]\]. The exact mechanism for carcinogenicity is unknown. It potentially produces the cytokines that regulate tumor growth, metastasis and angiogenesis. In addition, azathioprine also impair the ability to repair the genetic slicing through acting on the DNA and RNA ways \[[@R45]\]. Other studies have found that the use of mTORi may reduce the overall risk of solid cancers in KT recipients \[[@R15], [@R45]\]. Among latent infection patients, it is necessary to adjust the dose of immunosuppressant agents according to the patients' post-operation situation. Some studies also reported other known factors such as age, sex, history of smoking, underlying disease leading to transplantation and history of prior cancers, these known factors maybe influence deeply for the transplant recipients \[[@R44], [@R46]\]. For instance, if the recipients had a history of alcoholic liver cirrhosis, while in the study without excluding from the transplants, thus increasing the frequency of KT recipients at higher risk of liver cancer.

There are some limitations in this meta-analysis. 1) Despite the funnel plot and Egger's test showed the absence of publication bias, some important studies except for English publications or unpublished date related to our studies may have been missed, especially when the pooled increased estimate for liver cancer after transplantation was generated from the limited publications. 2) This meta-analysis included several different genetic background, medical situation, life styles, no detailed information for us to perform an adjustment for these potential confounders, such as the period of chronic hepatitis virus carrier, the period of alcoholic liver cirrhosis, obesity and so on. 3) In our collected data, although all studies used the general population as the reference population, the criteria used for matching might be different applied, 4) In our screened studies, two important indices, mean age at diagnosis of malignancy and mean time to develop liver cancer, were not measured in the included studies. 5) The renal transplant recipients were not screened for liver cancer before kidney transplantation (especially chronic hepatitis virus carrier). What's more, the length of time from transplantation to the diagnosis of the liver cancer was not clear in our results. So we could not exclude the recipients of possible pre-existing tumors in these recipients. 6) Related information on the type and the dosage of immunosuppressive agents were not available for the further subgroup analysis. Some studies demonstrated that low-dose cyclosporine was associated with a lower rate of malignancy than high-dose cyclosporine in RTRs \[[@R47]\].

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

In designing our meta-analysis, a systematic and comprehensive PubMed literature search and Web of Science Databases search updated through September 2015 was conducted to identify studies involving the risk of liver cancer in renal transplantation recipients. The search was restricted to studies published in English and to those including only humans. Search key terms used were 'renal transplantation', 'kidney transplantation', 'liver' and 'cancer'. The search results were restricted to the presence of the key terms in the title, abstracts and unpublished reports were excluded.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Eligible studies were selected for meta-analysis if they conform to the following inclusion criteria:(1) studies must be population-based cohort studies in renal transplantation recipients; (2) SIR were calculated with 95% confidence intervals in transplant recipients as compared to the general population. (3) Sufficient data on the incidence rate, SIR or relative risk (RR) of liver cancer and enough numbers of patients should be included in the studies. The following exclusion criteria were used: (1) other organ transplantation studies; (2) they were case series, case-control studies, or case reports; (3) they evaluated liver cancer following transplantation of organs other than the kidney; or (4) they evaluated cancers other than liver cancer following renal transplantation.

Data extraction {#s4_3}
---------------

The final date from all qualified publication were independently by two investigators (PC and TW) using the inclusion criteria above. They reached an agreement on all items after reducing any form of bias. Important information extracted from each study included: the first author, publication year, the type of transplantation, data source, geographic origin, number of patients, number of renal transplantation cases, length of follow-up time, number of all cancers in kidney transplant cases, mean follow-up time(years), patients-years(years), mean age at transplantation(years), number of expected cases of liver cancer, number of identified cases of liver cancer, and the SIRs of commonly known cancers and liver cancer.

Statistical analysis {#s4_4}
--------------------

In this meta-analysis, we obtained an estimate from each study of the unadjusted relative risk (RR) with 95% confidence intervals (CIs) to assess the strength of liver cancer in renal transplantation recipients compared to the general population. Because of possible heterogeneity in our studies, a random-effects model was used to pool effects for RR \[[@R48]\]. Heterogeneity between studies, namely differences in study outcomes, was calculated using the chi-squared-based Q-statistic test. The models of analysis for the pooled RRs were based on the P value. By estimating *I^2^*, which was documented for the percentage of the observed between study variability due to heterogeneity rather than chance, with *I^2^*\<25%, 25%-75% and \>75% representing low, moderate and high degree of inconsistency, respectively.

We assessed the effects of individual study data on the pooled RR through one-way sensitivity analysis. After the sequential removal of each study, the remaining studies could be used to evaluate the stability of the results. At the same time, we assessed publication bias by using a funnel plot and Begg's test to find out whether there was a bias towards publication of studies \[[@R49]\]. Funnel plot asymmetry was assessed using Egger's linear regression method on the natural logarithm scale of the RR. A symmetric plot suggested publication bias, with a P value \<0.05 indicating significant publication bias. All statistical analyses were performed using the STATE 11.0 software (version 11; STATA Corp, college station, TX, USA).

CONCLUSIONS {#s5}
===========

In conclusion, our meta-analysis showed an increased risk of developing liver carcinoma in transplant recipients (especially chronic hepatitis virus carrier). Renal transplant recipients should therefore be screened cautiously for their liver function and adjusted the dosage or period of immunosuppresive agents according to patients' clinical examination results. If they are the recipients with chronic hepatitis, periodic ultrasound and alpha fetoprotein monitering every 6-12 months are recommended among chronic hepatitis carriers because early detection of tumor can have a higher chance of receiving treatment \[[@R50]\].
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